Contractual Research

Individual solutions for individual therapies

Healthcare research in Germany is becoming increasingly important: high-quality data from standard care form the basis of the requirements and for answering various questions defined by the Federal Ministry of Education and Research (BMBF) in its funding programme and the Joint Federal Committee (G-BA) for the evaluation of new drugs or treatment procedures.

Relevant care research – your gain

A decisive aspect here is the recording of the entire course of the patient history, the longitudinal data, as well as inter-sectoral treatment data, i.e. outpatient and inpatient data. This is where the care research of GermanOncology comes in. Above all, its nationwide and constantly growing network enables GermanOncology to record and evaluate these extensive clinical parameters, progressions and treatment behaviour with oncological diseases. In addition, there is the analysis of related services and costs.

Our contractual research – more data for you

In addition to the continuous collection of anonymised data from standard care, GermanOncology also carries out targeted contract projects, for example, when:

further data are required from a tumour disease

further data are to be collected on the use of certain drugs

the quality of the data is to be improved through on-site data monitoring

the panel of data-providing practices is to be supplemented by other supply units, such as hospital consultancies, inpatient care or other specialist groups

Your advantages regarding contractual research:

Rapid implementation of the project in an existing, nationwide network

Selection option of the centres with the highest recruitment rates for the desired indication

Fast and cost-optimised configuration of the web-based software system Data4GO to the desired question

Biometric quota possibilities per centre

Support or complete assumption of project planning by experienced project management

Preparation of the biometric basis for the projects and statistical data evaluation by SAS/STAT

Innovative and timely evaluations through direct data transfer from Data4GO to SAS/STAT

Option for regular notification of project status by setting up an online platform for the client

Data monitoring with external collaboration partners under specified quality standards

Real World Data

Clinical and economic data from real patient care occupy an increasingly important area in the evaluation of therapies, since, unlike clinical studies, no patient selection takes place here and broad insights into therapies and the resulting costs can be gained.

The Basic Data Project

The analysis and presentation of clinical parameters, clinical processes and detailed treatment behaviour in individual therapy sequences are becoming increasingly important – both in large and, above all, in smaller tumour indications.

The basic data project, which has been running since 2012, offers a consistent and longitudinally updated recording of more than 20,000 patient histories under drug-based tumour therapy and an existing database through which various offers for data analyses with relevant case numbers can be implemented, or whose data can be expanded by targeted supplementary projects to answer specific questions.


Analysis of therapy behaviour for both common and rare tumour diseases

Analysis of the use of anti-tumour and supportive drugs

Analysis of relevant toxicities in individual therapy sequences

Analysis of the complete course of therapy as longitudinal observation

Cost and Revenue-Relevant Processes

The analysis and presentation of medical and technical performance data enable calculations of direct cost structures of individual therapy sections or entire patient histories. Among other things, all patients undergoing drug tumour therapy are documented anonymously in the centres of the participating oncologists. Due to this consistent data collection, we can implement various offers for data analysis with relevant case figures for you, such as, among others:


Analysis of the cost structures of individual treatment sections or the entire course of the patient

Analysis of net costs per patient for individual therapy measures in different therapy indications

Correlation of clinical benefit parameters with net costs per patient (basis cost-benefit assessment AMNOG procedure)

Analysis of the costs of different therapies in one indication as a basis for pricing and negotiations